Medical - Instruments & Supplies
Compare Stocks
2 / 10Stock Comparison
ANGO vs ISRG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
ANGO vs ISRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $466M | $159.85B |
| Revenue (TTM) | $307M | $10.58B |
| Net Income (TTM) | $-28M | $2.98B |
| Gross Margin | 53.7% | 66.3% |
| Operating Margin | -9.4% | 30.5% |
| Forward P/E | — | 43.3x |
| Total Debt | $0.00 | $303M |
| Cash & Equiv. | $56M | $3.37B |
ANGO vs ISRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| AngioDynamics, Inc. (ANGO) | 100 | 109.7 | +9.7% |
| Intuitive Surgical,… (ISRG) | 100 | 232.8 | +132.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ANGO vs ISRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ANGO is the clearest fit if your priority is momentum.
- +20.7% vs ISRG's -16.4%
ISRG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.00
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.5% 10Y total return vs ANGO's -9.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs ANGO's -3.8% | |
| Quality / Margins | 28.2% margin vs ANGO's -9.0% | |
| Stability / Safety | Beta 1.00 vs ANGO's 1.26 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +20.7% vs ISRG's -16.4% | |
| Efficiency (ROA) | 14.8% ROA vs ANGO's -10.3%, ROIC 15.0% vs -22.9% |
ANGO vs ISRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ANGO vs ISRG — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ISRG is the larger business by revenue, generating $10.6B annually — 34.4x ANGO's $307M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to ANGO's -9.0%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $307M | $10.6B |
| EBITDAEarnings before interest/tax | -$5M | $3.8B |
| Net IncomeAfter-tax profit | -$28M | $3.0B |
| Free Cash FlowCash after capex | -$9M | $2.8B |
| Gross MarginGross profit ÷ Revenue | +53.7% | +66.3% |
| Operating MarginEBIT ÷ Revenue | -9.4% | +30.5% |
| Net MarginNet income ÷ Revenue | -9.0% | +28.2% |
| FCF MarginFCF ÷ Revenue | -3.0% | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +9.0% | +23.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +42.3% | +18.8% |
Valuation Metrics
ANGO leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $466M | $159.8B |
| Enterprise ValueMkt cap + debt − cash | $410M | $156.8B |
| Trailing P/EPrice ÷ TTM EPS | -13.49x | 57.19x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 43.35x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.63x |
| EV / EBITDAEnterprise value multiple | — | 43.28x |
| Price / SalesMarket cap ÷ Revenue | 1.59x | 15.88x |
| Price / BookPrice ÷ Book value/share | 2.51x | 9.10x |
| Price / FCFMarket cap ÷ FCF | — | 64.18x |
Profitability & Efficiency
ISRG leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-16 for ANGO. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs ANGO's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -15.7% | +16.9% |
| ROA (TTM)Return on assets | -10.3% | +14.8% |
| ROICReturn on invested capital | -22.9% | +15.0% |
| ROCEReturn on capital employed | -18.6% | +16.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 |
| Debt / EquityFinancial leverage | — | 0.02x |
| Net DebtTotal debt minus cash | -$56M | -$3.1B |
| Cash & Equiv.Liquid assets | $56M | $3.4B |
| Total DebtShort + long-term debt | $0 | $303M |
| Interest CoverageEBIT ÷ Interest expense | -258.19x | — |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $16,174 today (with dividends reinvested), compared to $4,842 for ANGO. Over the past 12 months, ANGO leads with a +20.7% total return vs ISRG's -16.4%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.1% vs ANGO's 7.7% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -11.7% | -19.9% |
| 1-Year ReturnPast 12 months | +20.7% | -16.4% |
| 3-Year ReturnCumulative with dividends | +25.0% | +48.5% |
| 5-Year ReturnCumulative with dividends | -51.6% | +61.7% |
| 10-Year ReturnCumulative with dividends | -9.7% | +549.2% |
| CAGR (3Y)Annualised 3-year return | +7.7% | +14.1% |
Risk & Volatility
Evenly matched — ANGO and ISRG each lead in 1 of 2 comparable metrics.
Risk & Volatility
ISRG is the less volatile stock with a 1.00 beta — it tends to amplify market swings less than ANGO's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ANGO currently trades 80.1% from its 52-week high vs ISRG's 74.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.26x | 1.00x |
| 52-Week HighHighest price in past year | $13.99 | $603.88 |
| 52-Week LowLowest price in past year | $8.36 | $427.84 |
| % of 52W HighCurrent price vs 52-week peak | +80.1% | +74.5% |
| RSI (14)Momentum oscillator 0–100 | 57.5 | 43.6 |
| Avg Volume (50D)Average daily shares traded | 397K | 1.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ANGO as "Hold" and ISRG as "Buy". Consensus price targets imply 47.3% upside for ANGO (target: $17) vs 38.3% for ISRG (target: $623).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $16.50 | $622.60 |
| # AnalystsCovering analysts | 11 | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.4% | +1.4% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ANGO leads in 1 (Valuation Metrics). 1 tied.
ANGO vs ISRG: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is ANGO or ISRG a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -3. 8% for AngioDynamics, Inc. (ANGO). Intuitive Surgical, Inc. (ISRG) offers the better valuation at 57. 2x trailing P/E (43. 3x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ANGO or ISRG?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +61. 7%, compared to -51. 6% for AngioDynamics, Inc. (ANGO). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus ANGO's -9. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ANGO or ISRG?
By beta (market sensitivity over 5 years), Intuitive Surgical, Inc.
(ISRG) is the lower-risk stock at 1. 00β versus AngioDynamics, Inc. 's 1. 26β — meaning ANGO is approximately 26% more volatile than ISRG relative to the S&P 500.
04Which is growing faster — ANGO or ISRG?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus -3. 8% for AngioDynamics, Inc. (ANGO). On earnings-per-share growth, the picture is similar: AngioDynamics, Inc. grew EPS 81. 9% year-over-year, compared to 22. 6% for Intuitive Surgical, Inc.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ANGO or ISRG?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -11. 6% for AngioDynamics, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -13. 7% for ANGO. At the gross margin level — before operating expenses — ISRG leads at 66. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ANGO or ISRG more undervalued right now?
Analyst consensus price targets imply the most upside for ANGO: 47.
3% to $16. 50.
07Which pays a better dividend — ANGO or ISRG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ANGO or ISRG better for a retirement portfolio?
For long-horizon retirement investors, Intuitive Surgical, Inc.
(ISRG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00), +549. 2% 10Y return). Both have compounded well over 10 years (ISRG: +549. 2%, ANGO: -9. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ANGO and ISRG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ANGO is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.